Marlies de Graaf - Concepedia

Author

Marlies de Graaf

Also Known As

M Graaf, M de Graaf, M. de Graaf, Marlies De Graaf, Marlies Graaf, Marlies de Graaf, Marlies de Graaf, de Graaf, Michelle

108

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Utrecht Utrecht University Radboud University Nijmegen University Medical Center Groningen Radboud University Medical Center

About

Marlies de Graaf is an author at University Medical Center Utrecht specializing in medicine, dermatology, and pediatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	581
2	Allergy Medicine	4	4	94
3	Allergy	3	3	78
4	Public Health	1	1	16
5	Biomolecular Engineering	1	1	40

Marlies de Graaf

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Adverse effects of propranolol when used in the treatment of hemangiomas: A case series of 28 infants Marlies de Graaf, Johannes M. P. J. Breur, Martine F. Raphaël, Journal of the American Academy of Dermatology Pediatric HematologyHematologyPediatricsAdverse EffectsCase Series	2011	188
Hypoglycemia as a Result of Propranolol During Treatment of Infantile Hemangioma: A Case Report Johannes M. P. J. Breur, Marlies de Graaf, Corstiaan C. Breugem, Pediatric Dermatology Adrenal GlandPromising TreatmentCase ReportInfantile HemangiomaEndocrine Disease	2010	73
Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group Marlies de Graaf, M Raphaël, Corstiaan C. Breugem, Journal of Plastic Reconstructive & Aesthetic Surgery Infantile HaemangiomasPediatric HematologyPediatricsSurgeryHistorical Propranolol Group	2013	68
Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis Roselie Achten, Daphne S. Bakker, Lieneke F.M. Ariëns, The Journal of Allergy and Clinical Immunology In Practice OphthalmologyDupilumab TreatmentAtopic DermatitisModerate-to-severe Atopic DermatitisContact Dermatitis	2020	55
Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis Lotte S. Spekhorst, Daphne S. Bakker, Julia Drylewicz, Allergy	2022	54
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, JAMA Dermatology	2023	50
Detection and identification of FaeC as a minor component of K88 fibriilae of <i>Escherichia coli</i> Bauke Oudega, Marlies de Graaf, L. de Boer, Molecular Microbiology	1989	44
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis Lotte S. Spekhorst, Marlies de Graaf, Nicolaas P. A. Zuithoff, JAMA Dermatology	2022	42
Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters Daphne S. Bakker, Marlies de Graaf, Stefan Nierkens, Journal of Allergy and Clinical Immunology	2021	41
Secreted and tumour targeted human carboxylesterase for activation of irinotecan Dinja Oosterhoff, Herbert M. Pinedo, Ida H. van der Meulen, British Journal of Cancer Drug TargetingChemoprevention StrategyPolymer-drug ConjugateMedicineDrug Discovery	2002	40

Page 1